Literature DB >> 30167705

Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.

Henry R Kranzler1,2, Michael Soyka3,4.   

Abstract

Importance: Alcohol consumption is associated with 88 000 US deaths annually. Although routine screening for heavy alcohol use can identify patients with alcohol use disorder (AUD) and has been recommended, only 1 in 6 US adults report ever having been asked by a health professional about their drinking behavior. Alcohol use disorder, a problematic pattern of alcohol use accompanied by clinically significant impairment or distress, is present in up to 14% of US adults during a 1-year period, although only about 8% of affected individuals are treated in an alcohol treatment facility. Observations: Four medications are approved by the US Food and Drug Administration to treat AUD: disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate. However, patients with AUD most commonly receive counseling. Medications are prescribed to less than 9% of patients who are likely to benefit from them, given evidence that they exert clinically meaningful effects and their inclusion in clinical practice guidelines as first-line treatments for moderate to severe AUD. Naltrexone, which can be given once daily, reduces the likelihood of a return to any drinking by 5% and binge-drinking risk by 10%. Randomized clinical trials also show that some medications approved for other indications, including seizure disorder (eg, topiramate), are efficacious in treating AUD. Currently, there is not sufficient evidence to support the use of pharmacogenetics to personalize AUD treatments. Conclusions and Relevance: Alcohol consumption is associated with a high rate of morbidity and mortality, and heavy alcohol use is the major risk factor for AUD. Simple, valid screening methods can be used to identify patients with heavy alcohol use, who can then be evaluated for the presence of an AUD. Patients receiving a diagnosis of the disorder should be given brief counseling and prescribed a first-line medication (eg, naltrexone) or referred for a more intensive psychosocial intervention.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30167705     DOI: 10.1001/jama.2018.11406

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  119 in total

1.  Current Management of Alcohol-Associated Liver Disease.

Authors:  Faisal A Siddiqi; Krishna C Sajja; Nyan L Latt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-11

2.  Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test-Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder.

Authors:  Christopher T Rentsch; David A Fiellin; Kendall J Bryant; Amy C Justice; Janet P Tate
Journal:  Alcohol Clin Exp Res       Date:  2019-02-03       Impact factor: 3.455

Review 3.  Pharmacogenetics of alcohol use disorder treatments: an update.

Authors:  Emily E Hartwell; Henry R Kranzler
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-11       Impact factor: 4.481

4.  Understanding Addiction Using Animal Models.

Authors:  Brittany N Kuhn; Peter W Kalivas; Ana-Clara Bobadilla
Journal:  Front Behav Neurosci       Date:  2019-11-29       Impact factor: 3.558

5.  Documented brief intervention associated with reduced linkage to specialty addictions treatment in a national sample of VA patients with unhealthy alcohol use with and without alcohol use disorders.

Authors:  Madeline C Frost; Joseph E Glass; Katharine A Bradley; Emily C Williams
Journal:  Addiction       Date:  2019-12-11       Impact factor: 6.526

6.  Psychiatric comorbidities in alcohol use disorder.

Authors:  Alvaro Castillo-Carniglia; Katherine M Keyes; Deborah S Hasin; Magdalena Cerdá
Journal:  Lancet Psychiatry       Date:  2019-10-17       Impact factor: 27.083

Review 7.  Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions.

Authors:  Lloyd D Fricker; Elyssa B Margolis; Ivone Gomes; Lakshmi A Devi
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

Review 8.  Pharmacotherapeutic management of co-morbid alcohol and opioid use.

Authors:  Lauren E Hood; Jonna M Leyrer-Jackson; M Foster Olive
Journal:  Expert Opin Pharmacother       Date:  2020-02-27       Impact factor: 3.889

9.  Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats.

Authors:  Cassie M Chandler; Sarah E Maggio; Hui Peng; Kimberly Nixon; Michael T Bardo
Journal:  Drug Alcohol Depend       Date:  2020-04-25       Impact factor: 4.492

10.  Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.

Authors:  Robert L Cook; Zhi Zhou; Maria Jose Miguez; Clery Quiros; Luis Espinoza; John E Lewis; Babette Brumback; Kendall Bryant
Journal:  Alcohol Clin Exp Res       Date:  2019-07-10       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.